'On standalone basis
Quarter ended December 2024 compared with Quarter ended December 2023.
Net sales (including other operating income) of Supriya Lifescience has increased 32.54% to Rs 185.65 crore. Operating profit margin has jumped from 29.61% to 35.52%, leading to 58.99% rise in operating profit to Rs 65.95 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 34.42% to 9.89%. Employee cost increased from 13.48% to 14.38%. Other expenses rose from 20.27% to 27.75%.
Other income fell 31.60% to Rs 2.1 crore. PBIDT rose 52.75% to Rs 68.05 crore. Provision for interest up 4.08% to Rs 0.51 crore.
PBDT rose 53.29% to Rs 67.54 crore. Provision for depreciation rose 25.25% to Rs 4.96 crore.
Profit before tax grew 56.06% to Rs 62.58 crore. Provision for tax was expense of Rs 15.8 crore,...
Pleaselogin & subscribe to view the full report.
More Reports
-
(04-May-2025)
State Bank of India
Profit declines on high provisions, asset quality remains healthy
-
(04-May-2025)
Indian Bank
Strong retail loan growth, robust asset quality
-
(04-May-2025)
Avenue Supermarts
Revenue up 16.9% YoY, Net profit down 2.2% YoY in Q4FY2025
-
(04-May-2025)
Vardhman Textiles
Net profit up 40.0% YoY to Rs 883.3 crore in FY2025
|
|